Vascular Biogenics Ltd (VBLT)

[gr8db8]

VB-111 to become first line treatment for rGBM

Avastin is the first approved angiogenesis inhibitor. It has been a blockbuster drug for Roche and has been approved for various kinds of cancer including glioblastoma (GBM). Vascular Biogenics is targeting recurrent GBM or rGBM. Interim results from Phase 2 trial of VB-111 in rGBM has already shown that the drug has a better safety and efficacy profile compared to Avastin. The interim results were reported at the Drug Discovery and Therapy World Congress (DDTWC) in July this year and showed a "strengthened, statistically significant overall survival in patients treated with VB-111 followed by VB-111 in combination with bevacizumab upon disease progression, compared to patients treated with VB-111 followed by bevacizumab alone.

VBLT is aiming to make VB-111 a first-line treatment for rGBM. Avastin is a second-line treatment. VB-111 has already shown to have a better safety profile than Avastin so if approved, VB-111 could become a first-line treatment in rGBM. The data on Sunday could further establish the case for making VB-111 a first-line treatment.

In the U.S. alone, VBLT's addressable market would be worth around $1.3 billion to $1.4 billion based on the number of rGBM cases and treatment cost of around $100,000.

http://seekingalpha.com/article/3530976-premarket-biotech-digest-essure-future-vascular-biogenics-data-oncogenexs-apatorsen-fails